Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis
- 1 April 2002
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 146 (4), 707-709
- https://doi.org/10.1046/j.1365-2133.2002.46833.x
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Toxische epidermale Nekrolyse (Arzneimittel-induziertes Lyell-Syndrom) - Teil 1: Klinik und Differentialdiagnose¹ -Deutsche Medizinische Wochenschrift (1946), 2001
- Toxic Epidermal Necrolysis (TEN) in Elderly PatientsJournal of Burn Care & Rehabilitation, 2001
- Toxische epidermale Nekrolysen (Arzneimittel-induziertes Lyell-Syndrom)Deutsche Medizinische Wochenschrift (1946), 2001
- Management of toxic epidermal necrolysisHospital Medicine, 2000
- Immunoregulatory Effector Cells in Drug-Induced Toxic Epidermal NecrolysisThe American Journal of Dermatopathology, 2000
- Adverse cutaneous drug reactions in patients with human immunodeficiency virus-1 infectionClinics in Dermatology, 2000
- Thalidomide in toxic epidermal necrolysisThe Lancet, 1999
- Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysisThe Lancet, 1998
- Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysisBritish Journal of Dermatology, 1996
- Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysisArchives of Dermatology, 1994